Franchises et coassurance : Questions médicales fréquentes
Nom anglais: Deductibles and Coinsurance
Descriptor UI:D003669
Tree Number:N03.219.521.576.090.300
Termes MeSH sélectionnés :
Ophthalmic Solutions
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Franchises et coassurance : Questions médicales les plus fréquentes",
"headline": "Franchises et coassurance : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Franchises et coassurance : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-08",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Franchises et coassurance"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Participation aux coûts",
"url": "https://questionsmedicales.fr/mesh/D017047",
"about": {
"@type": "MedicalCondition",
"name": "Participation aux coûts",
"code": {
"@type": "MedicalCode",
"code": "D017047",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N03.219.521.576.090"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Franchises et coassurance",
"alternateName": "Deductibles and Coinsurance",
"code": {
"@type": "MedicalCode",
"code": "D003669",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "J Frank Wharam",
"url": "https://questionsmedicales.fr/author/J%20Frank%20Wharam",
"affiliation": {
"@type": "Organization",
"name": "Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA."
}
},
{
"@type": "Person",
"name": "Alisa B Busch",
"url": "https://questionsmedicales.fr/author/Alisa%20B%20Busch",
"affiliation": {
"@type": "Organization",
"name": "Department of Health Care Policy, Harvard Medical School."
}
},
{
"@type": "Person",
"name": "Fang Zhang",
"url": "https://questionsmedicales.fr/author/Fang%20Zhang",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Dennis Ross-Degnan",
"url": "https://questionsmedicales.fr/author/Dennis%20Ross-Degnan",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Mark K Meiselbach",
"url": "https://questionsmedicales.fr/author/Mark%20K%20Meiselbach",
"affiliation": {
"@type": "Organization",
"name": "Health Policy and Management, Johns Hopkins University, Baltimore, Maryland, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Reduced Posology of an Ophthalmic Hydrogel Containing Dexamethasone/Netilmicin to Prevent and Treat Ocular Inflammation After Cataract Surgery: Efficacy and Tolerability.",
"datePublished": "2022-10-07",
"url": "https://questionsmedicales.fr/article/36203046",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12325-022-02295-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Allergic Conjunctivitis Management: Update on Ophthalmic Solutions.",
"datePublished": "2024-06-13",
"url": "https://questionsmedicales.fr/article/38869807",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11882-024-01150-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36164414",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/DDDT.S370559"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation.",
"datePublished": "2023-03-14",
"url": "https://questionsmedicales.fr/article/36940502",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.colsurfb.2023.113267"
}
},
{
"@type": "ScholarlyArticle",
"name": "Compound electrolyte intraocular irrigating solution produces better effects on vision recovery of cataract patients after surgery than Ringer lactate solution.",
"datePublished": "2024-06-17",
"url": "https://questionsmedicales.fr/article/38886282",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10792-024-03131-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Organisations et économie des soins de santé",
"item": "https://questionsmedicales.fr/mesh/D004472"
},
{
"@type": "ListItem",
"position": 3,
"name": "Économie",
"item": "https://questionsmedicales.fr/mesh/D004467"
},
{
"@type": "ListItem",
"position": 4,
"name": "Financement organisé",
"item": "https://questionsmedicales.fr/mesh/D005381"
},
{
"@type": "ListItem",
"position": 5,
"name": "Assurance",
"item": "https://questionsmedicales.fr/mesh/D007341"
},
{
"@type": "ListItem",
"position": 6,
"name": "Participation aux coûts",
"item": "https://questionsmedicales.fr/mesh/D017047"
},
{
"@type": "ListItem",
"position": 7,
"name": "Franchises et coassurance",
"item": "https://questionsmedicales.fr/mesh/D003669"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Franchises et coassurance - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Franchises et coassurance",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Franchises et coassurance",
"description": "Qu'est-ce qu'une franchise en assurance santé ?\nComment fonctionne la coassurance ?\nQuelle est la différence entre franchise et coassurance ?\nComment sont calculées les franchises ?\nLes franchises sont-elles remboursables ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Franchises et coassurance",
"description": "Quels sont les impacts d'une franchise élevée ?\nComment la coassurance affecte-t-elle les patients ?\nLes patients ressentent-ils du stress à cause des franchises ?\nLes franchises influencent-elles la santé des patients ?\nY a-t-il des symptômes financiers liés à la coassurance ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Franchises et coassurance",
"description": "Comment éviter des frais élevés de franchise ?\nLes bilans de santé sont-ils couverts sans franchise ?\nComment éduquer les patients sur les franchises ?\nLes programmes de prévention réduisent-ils les coûts ?\nComment les patients peuvent-ils planifier leurs soins ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Franchises et coassurance",
"description": "Comment choisir un plan avec franchise ?\nLes traitements préventifs sont-ils couverts ?\nComment réduire les coûts de coassurance ?\nLes médicaments sont-ils soumis à la franchise ?\nLes soins d'urgence sont-ils affectés par la coassurance ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Franchises et coassurance",
"description": "Quelles complications peuvent survenir avec des franchises élevées ?\nLa coassurance peut-elle entraîner des complications financières ?\nLes patients évitent-ils des soins à cause des coûts ?\nComment les complications de santé affectent-elles les coûts ?\nLes complications dues à la coassurance sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Franchises et coassurance",
"description": "Quels facteurs augmentent les coûts de franchise ?\nComment le choix de l'assurance affecte-t-il les coûts ?\nLes maladies chroniques augmentent-elles les frais ?\nLes jeunes adultes ont-ils des franchises plus basses ?\nLes habitudes de santé influencent-elles les coûts ?",
"url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=Ophthalmic+Solutions&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Qu'est-ce qu'une franchise en assurance santé ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est le montant que le patient doit payer avant que l'assurance ne couvre les frais."
}
},
{
"@type": "Question",
"name": "Comment fonctionne la coassurance ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est le pourcentage des frais médicaux que le patient doit payer après la franchise."
}
},
{
"@type": "Question",
"name": "Quelle est la différence entre franchise et coassurance ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La franchise est un montant fixe, tandis que la coassurance est un pourcentage des frais."
}
},
{
"@type": "Question",
"name": "Comment sont calculées les franchises ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement fixées par le contrat d'assurance et varient selon les plans."
}
},
{
"@type": "Question",
"name": "Les franchises sont-elles remboursables ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les montants de franchise ne sont pas remboursés par l'assurance."
}
},
{
"@type": "Question",
"name": "Quels sont les impacts d'une franchise élevée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une franchise élevée peut dissuader les patients de consulter des soins médicaux."
}
},
{
"@type": "Question",
"name": "Comment la coassurance affecte-t-elle les patients ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des coûts supplémentaires pour les patients lors de soins médicaux."
}
},
{
"@type": "Question",
"name": "Les patients ressentent-ils du stress à cause des franchises ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les coûts imprévus peuvent causer de l'anxiété financière chez les patients."
}
},
{
"@type": "Question",
"name": "Les franchises influencent-elles la santé des patients ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent limiter l'accès aux soins, affectant ainsi la santé globale des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes financiers liés à la coassurance ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des frais médicaux imprévus peuvent entraîner des difficultés financières."
}
},
{
"@type": "Question",
"name": "Comment éviter des frais élevés de franchise ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Choisissez un plan avec une franchise adaptée à vos besoins médicaux prévisibles."
}
},
{
"@type": "Question",
"name": "Les bilans de santé sont-ils couverts sans franchise ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les bilans de santé préventifs sont couverts sans frais de franchise."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les franchises ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fournissez des informations claires sur les coûts et les options d'assurance disponibles."
}
},
{
"@type": "Question",
"name": "Les programmes de prévention réduisent-ils les coûts ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent réduire les coûts à long terme en évitant des soins coûteux."
}
},
{
"@type": "Question",
"name": "Comment les patients peuvent-ils planifier leurs soins ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils doivent évaluer leurs besoins et choisir des soins en fonction de leur plan d'assurance."
}
},
{
"@type": "Question",
"name": "Comment choisir un plan avec franchise ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluez vos besoins médicaux et comparez les coûts des franchises et coassurances."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs sont-ils couverts ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les traitements préventifs sont couverts sans franchise, selon le plan."
}
},
{
"@type": "Question",
"name": "Comment réduire les coûts de coassurance ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Choisissez des soins dans le réseau de votre assurance pour réduire les frais."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils soumis à la franchise ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent être soumis à la franchise selon le plan d'assurance."
}
},
{
"@type": "Question",
"name": "Les soins d'urgence sont-ils affectés par la coassurance ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les soins d'urgence peuvent entraîner des frais de coassurance après la franchise."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des franchises élevées ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients peuvent retarder des soins nécessaires, entraînant des complications de santé."
}
},
{
"@type": "Question",
"name": "La coassurance peut-elle entraîner des complications financières ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des frais imprévus peuvent causer des dettes médicales importantes."
}
},
{
"@type": "Question",
"name": "Les patients évitent-ils des soins à cause des coûts ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les coûts élevés peuvent dissuader les patients de rechercher des soins médicaux."
}
},
{
"@type": "Question",
"name": "Comment les complications de santé affectent-elles les coûts ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent entraîner des frais médicaux supplémentaires et imprévus."
}
},
{
"@type": "Question",
"name": "Les complications dues à la coassurance sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux patients rencontrent des difficultés à payer leurs frais médicaux."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent les coûts de franchise ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, les antécédents médicaux et le type de soins peuvent influencer les coûts."
}
},
{
"@type": "Question",
"name": "Comment le choix de l'assurance affecte-t-il les coûts ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Différents plans d'assurance ont des franchises et coassurances variées, influençant les coûts."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles les frais ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients avec des maladies chroniques peuvent faire face à des frais plus élevés."
}
},
{
"@type": "Question",
"name": "Les jeunes adultes ont-ils des franchises plus basses ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les jeunes adultes choisissent des plans avec des franchises plus basses."
}
},
{
"@type": "Question",
"name": "Les habitudes de santé influencent-elles les coûts ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de santé positives peuvent réduire les frais médicaux à long terme."
}
}
]
}
]
}
To demonstrate efficacy and safety of an ophthalmic hydrogel formulation of netilmicin/dexamethasone, containing xanthan gum twice a day (b.i.d.) versus netilmicin/dexamethasone eye drops four times a...
Patients undergoing phacoemulsification with intraocular lens implantation (IOL) were randomised in two groups: group 1, twice daily (b.i.d.) dexamethasone 0.1%/netilmicin 0.3% (Netildex) ophthalmic g...
One hundred seventy-three patients were randomised and 168 were evaluable. Flare and cellularity were resolved at day 7 in 92.5% of patients and almost completely by day 15. In both intent to treat (I...
Efficacy of the gel reduced posology (twice a day) is not inferior to four times a day eye drops. Both treatments were well tolerated and efficacious. The new reduced posology hydrogel formulation may...
Eudract: 2016-0021138-63; ClinicalTrial.gov: NCT029738880....
The aim of this review, is to present an updated revision of topical management of SAC and PAC, based on the available scientific evidence and focused on the impact of ophthalmic solution formulations...
Physicians treating ocular allergy should be aware of tear film and tear film disruption in SAC and PAC, and how eye drop composition and additives affect the physiology of the allergic eye. Seasonal ...
To confirm the efficacy and safety of a novel ophthalmic cyclosporine A gel (CyclAGel, 0.05% CsA) in treating patients with moderate-to-severe dry eye disease (DED)....
The COSMO trial was a randomized, multicenter, double-masked, vehicle-controlled, phase III trial. Patients with moderate-to-severe DED were enrolled in 37 hospitals in China between November 2020 and...
The full analysis set (FAS) included 315 and 312 participants in the CyclAGel and vehicle groups, respectively. The primary efficacy endpoint was achieved. The proportion of subjects with at least a 1...
Clinically and statistically significant improvements in ICSS, tear production, and symptoms were observed in participants administered CyclAGel 0.05% QD for moderate-to-severe DED. CyclAGel 0.05% QD ...
Herein, cyclosporine A loaded liposomes (CsA-Lips) were fabricated aimed at improving the biocompatibility of the ophthalmic formulation and getting rid of the direct contact of ocular tissues with ir...
Intraocular irrigating solution is extensively applied in cataract surgery. This paper explored the difference and relationship between optical coherence tomography (OCT) and optical quality analysis ...
Totally 200 senior cataract patients were randomly divided into the CEIIS and RL groups (N = 100 patients/group). The anterior chamber was irrigated by CEIIS or RL during phacoemulsification. Patients...
There were no significant differences in clinical characteristics between the CEIIS and RL groups. Both groups exhibited notably increased postoperative CMT, MTF cutoff, SR, OV at 100%, 20%, and 9% co...
CEIIS surpasses RL in postoperative visual recovery and retards increases of macular HF numbers and CMT in senior DM+ cataract patients....
Evaluate safety and efficacy of 0.75% phentolamine ophthalmic solution (POS), an alpha-1 antagonist, in reversal of pharmacologically induced mydriasis....
Two Phase 3, multicenter, placebo-controlled, randomized, double-masked clinical trials in healthy subjects....
553 healthy 12 to 80 year old subjects were randomized 1:1 (MIRA-2) and 2:1 (MIRA-3) to receive either POS or placebo eye drops OU....
Subjects received POS or placebo administered 1 hour after mydriasis, induced by instillation of either 2.5% phenylephrine, 1% tropicamide, or Paremyd (1% hydroxyamphetamine / 0.25% tropicamide)....
Primary endpoint was percent of subjects returning to ≤0.2 mm greater than baseline pupil diameter in study eye at 90 minutes after POS administration. Safety measures included treatment-emergent adve...
In MIRA-2, 185 subjects were randomized to treatment with placebo (94) or POS (91). In MIRA-3, 368 subjects were randomized to treatment with placebo (124) or POS (244). A statistically significant gr...
POS treatment had a rapid onset in reducing PD within 60- to 90-minutes, with a statistically significant time savings of 3 to 4 hours to return to baseline PD compared to placebo. One or 2 drops of P...
The aim of this paper is to research the impact of calf blood-deproteinized extract ophthalmic gel combined with sodium hyaluronate eye drops on conjunctival hyperemia score and tear film stability in...
144 patients having dry eye disease who were hospitalized from July 2018 to July 2021 were chosen as the research targets, which were composed of the control group and research group on the basis of t...
After the treatments of 2 weeks and later 1 month, the numerical values of the conjunctival hyperemia were fewer in the categories which had been mentioned above, and in contrast with the control one ...
In order for the treatments of patients having dry eye disease, the use of calf blood-deproteinized extract ophthalmic gel having the combinations with eye drops of sodium hyaluronate can enhance the ...
Keratoconjunctivitis sicca or dry eye disease (DED) is a multifactorial disorder underpinned by a complex inflammatory cycle. Introduction of topical cyclosporine has been a significant advance in the...
We compared two dosing regimes of a proprietary MNP cyclosporine emulsion with the widely marketed topical cyclosporine formulation Restasis™ in a multicenter parallel-group randomised trial in patien...
Corneal fluorescein staining score, the primary efficacy endpoint, decreased by 6.8 ± 4.0, 5.7 ± 3.9, and 4.6 ± 3.6 points in the 3 groups respectively, indicating superior efficacy in test arm A in c...
The results indicate that the dose of 1 drop of a 0.05% w/v ophthalmic emulsion of MNP cyclosporine administered topically twice daily yields better outcomes at 12 weeks than the lower dose tested in ...
This trial was registered in the Clinical Trials Registry of India on 29/03/2019, and was assigned registration number CTRI/2019/03/018319....
An enavogliflozin ophthalmic solution (DWRX2008) is being developed to treat diabetic retinopathy and macular edema. This study evaluated the ocular distribution and plasma pharmacokinetics (PKs) of e...
